flow of patients through the trial nissen se, et al. jama 2008;299:1561-73
DESCRIPTION
Baseline and On-Treatment Vital Signs and Laboratory Values in Participants Completing the Trial (n=360) a Nissen SE, et al. JAMA 2008;299:TRANSCRIPT
![Page 1: Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73](https://reader036.vdocument.in/reader036/viewer/2022062907/5a4d1b767f8b9ab0599b7364/html5/thumbnails/1.jpg)
Flow of Patients Through the Trial
Nissen SE, et al. JAMA 2008;299:1561-73
![Page 2: Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73](https://reader036.vdocument.in/reader036/viewer/2022062907/5a4d1b767f8b9ab0599b7364/html5/thumbnails/2.jpg)
Baseline Demographic Characteristics and Medications at the Time of Randomization
Nissen SE, et al. JAMA 2008;299:1561-73
![Page 3: Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73](https://reader036.vdocument.in/reader036/viewer/2022062907/5a4d1b767f8b9ab0599b7364/html5/thumbnails/3.jpg)
Baseline and On-Treatment Vital Signs and Laboratory Values in Participants Completing the Trial (n=360)a
Nis
sen
SE
, et a
l. JA
MA
200
8;29
9:15
61-7
3
![Page 4: Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73](https://reader036.vdocument.in/reader036/viewer/2022062907/5a4d1b767f8b9ab0599b7364/html5/thumbnails/4.jpg)
Changes in Mean Hemoglobin A1c, Fasting Plasma Glucose Levels, High-Density Lipoprotein Cholesterol, and C-Reactive Protein During the Trial (n = 360)
Nis
sen
SE
, et a
l. JA
MA
200
8;29
9:15
61-7
3
![Page 5: Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73](https://reader036.vdocument.in/reader036/viewer/2022062907/5a4d1b767f8b9ab0599b7364/html5/thumbnails/5.jpg)
Baseline, Follow-up, and Change From Baseline in Intravascular Ultrasound End Points
Nissen SE, et al. JAMA 2008;299:1561-73
![Page 6: Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73](https://reader036.vdocument.in/reader036/viewer/2022062907/5a4d1b767f8b9ab0599b7364/html5/thumbnails/6.jpg)
Primary Efficacy Parameter (Percent Atheroma Volume) in Prespecified Subgroups
Nis
sen
SE
, et a
l. JA
MA
200
8;29
9:15
61-7
3
![Page 7: Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73](https://reader036.vdocument.in/reader036/viewer/2022062907/5a4d1b767f8b9ab0599b7364/html5/thumbnails/7.jpg)
Change From Baseline in Intravascular Ultrasound End Points Using Imputed Values for Noncompleters
Nissen SE, et al. JAMA 2008;299:1561-73
![Page 8: Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73](https://reader036.vdocument.in/reader036/viewer/2022062907/5a4d1b767f8b9ab0599b7364/html5/thumbnails/8.jpg)
Clinical End Points, Adverse Events, Laboratory Abnormalities, and Reasons for Discontinuing Participation (Safety Population, n = 543)
Nis
sen
SE
, et a
l. JA
MA
200
8;29
9:15
61-7
3